Eterna Therapeutics Inc (ERNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eterna Therapeutics Inc (ERNA) has a cash flow conversion efficiency ratio of -0.356x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.27 Million) by net assets ($3.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Eterna Therapeutics Inc (ERNA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Eterna Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Eterna Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Eterna Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eterna Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Silver Range Resources Ltd
V:SNG
|
-0.019x |
|
ZHONGLIANG HLDG HD-01
F:3ZH
|
N/A |
|
Rain Enhancement Technologies Holdco, Inc. Class A Common Stock
NASDAQ:RAIN
|
0.026x |
|
Saraswati Griya Lestari Tbk
JK:HOTL
|
-0.001x |
|
Invert Graphite Limited
AU:IVG
|
-0.141x |
|
J-Long Group Limited
NASDAQ:JL
|
-0.044x |
|
Prasidha Aneka Niaga Tbk
JK:PSDN
|
-0.096x |
|
HYDROGEN UTOPIA INT.-001
F:D60
|
N/A |
Annual Cash Flow Conversion Efficiency for Eterna Therapeutics Inc (2007–2024)
The table below shows the annual cash flow conversion efficiency of Eterna Therapeutics Inc from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Eterna Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.70 Million | $-15.84 Million | -9.310x | -1.87% |
| 2023-12-31 | $2.23 Million | $-20.41 Million | -9.139x | -427.50% |
| 2022-12-31 | $12.11 Million | $-20.98 Million | -1.733x | -88.13% |
| 2021-12-31 | $25.50 Million | $-23.49 Million | -0.921x | +12.93% |
| 2020-12-31 | $7.66 Million | $-8.10 Million | -1.058x | -296.24% |
| 2019-12-31 | $5.09 Million | $2.74 Million | 0.539x | +173.13% |
| 2018-12-31 | $6.92 Million | $1.36 Million | 0.197x | +98.99% |
| 2017-12-31 | $5.54 Million | $549.00K | 0.099x | +1654.00% |
| 2016-12-31 | $4.07 Million | $23.00K | 0.006x | +100.52% |
| 2015-12-31 | $3.85 Million | $-4.18 Million | -1.086x | -85.85% |
| 2014-12-31 | $10.92 Million | $-6.38 Million | -0.584x | -460.25% |
| 2013-12-31 | $9.20 Million | $1.49 Million | 0.162x | -40.59% |
| 2012-12-31 | $7.89 Million | $2.16 Million | 0.273x | +202.14% |
| 2011-12-31 | $6.35 Million | $574.00K | 0.090x | -69.79% |
| 2010-12-31 | $9.46 Million | $2.83 Million | 0.299x | +12.59% |
| 2009-12-31 | $9.42 Million | $2.50 Million | 0.266x | +100.69% |
| 2007-12-31 | $15.57 Million | $-604.00 Million | -38.798x | -- |
About Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the tr… Read more